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     BSTRACT
A fourteen-year-old Persian cat was referred because of poorly controlled diabetes mellitus 
despite insulin and dietary treatment. Clinical signs were severe polydipsia/polyuria (pupd), 
poor hair coat quality, stomatitis and hind limb weakness. At the time of initial presentation, he 
was treated with glargine insulin (0,75 IU/kg BID). A low dose dexamethasone suppression test 
(LDDST) revealed hypercortisolism (HC). The cat was additionally treated with trilostane, and 
remission of diabetes mellitus was obtained one year later. 
This case illustrates the importance of diagnosing an underlying cause of poorly controlled 
diabetes mellitus. Although hypercortisolism is rare in cats, it is important to consider the disease 
in these cases. The hypercortisolism in this cat was efficiently managed with trilostane, resulting 
in a good quality of life.
SAMENVATTING
Een veertien jaar oude Perzische kat werd doorverwezen vanwege slecht gereguleerde diabetes mellitus 
ondanks insulinebehandeling en een aangepast dieet. De kat vertoonde uitgesproken polyurie/polydipsie, 
een slechte vachtkwaliteit, stomatitis en zwakte op de achterhand. Op dat moment werd hij behandeld 
met glargine insuline (0,75 IE/kg BID). Met behulp van een lage-dosis-dexamethasone-suppressie-test 
(LDDST) werd hypercortisolisme (HC) gediagnostiseerd. De kat werd bijkomend behandeld met trilostane 
en één jaar later werd remissie van diabetes mellitus bekomen. 
Deze casuïstiek illustreert het belang van de diagnose van een onderliggende oorzaak van slecht 
gereguleerde diabetes mellitus. Ook al is hypercortisolisme zeldzaam bij katten, het is belangrijk de 
ziekte bij deze gevallen in de differentiaaldiagnose op te nemen. Hypercortisolisme werd bij deze patiënt 
behandeld met trilostane, resulterend in een goede levenskwaliteit. 
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INTRODUCTION
Diabetes mellitus (DM) is a common endocrine 
disease in cats. It is defined as a relative or absolute in-
sulin deficiency that causes persistent hyperglycemia. 
The classification of DM is based on the mechanism 
of insulin deficiency. In analogy with human classifi-
cation, it can be divided in type 1, type 2 and ‘other 
specific types’ of diabetes. Approximately 80 to 95 % 
of diabetic cats are thought to have type 2 diabetes 
mellitus (Rand, 2013; Gostelow et al., 2014).
Type 2 initiates with a relative deficiency of insulin 
that later becomes an absolute deficiency. Factors that 
contribute to insulin resistance are genotype, obesity, 
physical inactivity and diet. The β-cells try to com-
pensate by secreting more insulin. The chronic high 
demand for insulin leads to β-cell failure and loss 
through apoptosis causing insulin deficiency (Niessen 
et al., 2013; Rand, 2013). 
The management of diabetic cats can be challeng-
ing. In these cases, the etiopathogenesis of DM may 
not be type 2 but an underlying disease. This type is 
categorized as ‘other specific types of diabetes’. Some 
of these diseases, such as pancreatitis and pancreatic 
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neoplasia, destroy β-cells. Other diseases, such as hy-
persomatotropism and hypercortisolism, induce dia-
betes by producing an excess of growth hormone and 
cortisol, respectively. These hormones cause insulin 
resistance (Rand, 2013; Niessen et al., 2013). Cur-
rently, hypersomatotropism is thought to be the un-
derlying disease in feline DM in 25 to 30% of cases 
(Rand and Gottlieb, 2017). 
Insulin resistance can be an important component 
of the pathogenesis of diabetes mellitus secondary to 
an underlying disease. Resolution of peripheral in-
sulin resistance together with good glycemic control 
may result in remission of feline diabetes (Scott-Mon-
crieff, 2010). 
Contrary to dogs, hypercortisolism (HC) is rare 
in cats. The main differences and similarities in HC 
between dogs and cats are summarized in Table 1. In 
most cases (85 %), HC is caused by a tumor of the pi-
tuitary gland (pituitary-dependent HC). The elevated 
secretion of adrenocorticotropic hormone (ACTH) 
causes hyperplasia of both adrenal glands and an 
increase in production of cortisol. In approximately 
15 % of HC in cats, it is caused by functional adre-
nal tumors that autonomously secrete cortisol. Fifty 
percent are malignant adenocarcinomas (Bhatti and 
Daminet, 2004; Chiaramonte and Greco, 2007; Feld-
man, 2014). 
In this article, a cat with DM and HC is described. 
Medical treatment of HC in cats with trilostane is fur-
ther addressed.  
CASE REPORT
A fourteen-year-old, male, castrated Persian cat 
of 5.25 kg was presented at the Small Animal Clin-
ic, Faculty of Veterinary Medicine (Ghent Univer-
sity) for poorly controlled DM (day 0). Four months 
before, diabetes mellitus had been diagnosed and 
therapy with insulin (Caninsulin®, MSD Animal 
Health, Brussels, Belgium) was initiated. The insu-
lin dose was gradually increased to 6 IU BID (1.14 
IU/kg) based on blood glucose curves, performed at 
home (HMBG), still showing poorly controlled DM. 
Baseline data (complete blood count, biochemistry 
profile, electrolytes) were obtained by the referring 
veterinarian at the time of diagnosis. Values were 
within normal limits. IGF-1, measured by the refer-
ring veterinarian after six weeks of insulin treatment, 
was 21.4 nmol/L (163 μg/L) (1.4 (10.7) – 53.8 (411)). 
Three months after diagnosis, therapy was changed 
to glargine (Lantus®, Sanofi-Aventis, Frankfurt am 
Main, Germany). At the time of presentation at the 
Small Animal Clinic, the cat received 4 IU BID (0.75 
IU/kg), without significant improvement. 
The patient presented with persistent pupd, poor 
hair coat and discoloration and hind limbs weakness 
(Figures 1 and 2). The body condition score was 6/9 
and the cat was fed a diabetic diet ad libitum (Royal 
Canin Diabetic®). 
On physical examination, stomatitis, halitosis and 
mild hepatomegaly were noticed. To search for un-
derlying diseases and assess the adrenal glands, an 
abdominal ultrasound was performed and revealed 
mild hepatomegaly with a homogenous hyperechoic 
parenchyma, suggestive of lipidosis. Both adrenal 
glands had a normal shape, the left gland was normal 
in size (4.1 mm), whereas the right gland was mildly 
enlarged (5.6 mm) (Figure 3). The mildly enlarged 
right adrenal gland could be an incidental finding, i.e. 
anatomical variation, measurement variability. How-
ever hyperplasia secondary to pituitary disease (PDH 
or acromegaly) or an early adrenal tumor could not 
be excluded. Urinalysis including culture showed glu-
cosuria and isosthenuria but no bacterial cystitis. As 
Figure 1. Poor hair coat quality and discoloration. 
Figure 2. Alopecia of the ventral abdomen. 
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the dose of insulin administered was not yet at a level 
suggestive of insulin resistance (>1.5 IU/kg BID), the 
initial advice was to increase the dose of glargine to 
4.5 IU BID (0.8 IU/kg), to treat the stomatitis (detar-
tration and extraction of affected teeth) and to pro-
mote weight loss (Sparkes et al., 2015). Insulin mana-
gement errors were considered and ruled out. Other 
causes of insulin resistance and additional work-up 
were discussed with the owner in case no improve-
ment would be observed. 
Four weeks later (day 27), the cat was receiving 5 
IU BID (0.95 IU/kg) of glargine but the same signs 
were still present. A low dose (0.1 mg/kg) dexametha-
sone suppression test (LDDST) was performed and 
confirmed HC (Table 2). In some cases, this test can 
also allow to make a differentiation between pitui-
tary-dependent (PDH) and adrenal-dependent HC 
(ADH) based on the level of suppression of cortisol. 
In this case, there was suppression after four hours 
(<40 nmol/L) and an escape of suppression after eight 
Figure 3. Ultrasound image of the adrenal glands. A. Longitudinal image of the left adrenal gland, and B. transverse 
image at the level of the caudal pole of the right adrenal gland. The calipers (yellow ++) indicate the height of the cau-
dal pole. 
A B
Table 1. The main differences of hypercortisolism between dogs and cats (Bhatti and Daminet, 2004; Nelson, 2014; 
Boland and Barrs, 2017).
 Dogs  Cats
Signalment Breed predisposition ≠  No breed predisposition
 Older dogs  = Older cats (>10 years)
 More in female dogs  ≠  More male cats (54%)
Location  PDH (85%) = PDH  (85%)
 ADH (15%)  ADH (15%)
History Some have DM (10%) ≠ Most have DM (80%)
Clinical signs and physical Pupd = Pupd
examination (common findings) Polyphagia   Polyphagia
 Abdominal distention  Abdominal distention
 Endocrine alopecia  Endocrine alopecia
 Weakness  Lethargy
 Hepatomegaly   Hepatomegaly 
 Epidermal atrophy   1/3 have extreme skin fragility
 Panting  ≠ Weight loss
 
ALF Often iso-enzym is induced  ≠ No increase of iso-enzym
USG Markedly decreased  ≠ Usually > 1.020
Endocrine tests  LDDST (0,01 mg/kg IV) ≠ LDDST (0,1 mg/kg IV)
 UCCR =  UCCR
Medical therapy  Trilostane  = Trilostane
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hours of administering dexamethasone. This is sug-
gestive of PDH (Feldman, 2014; Boland and Barrs, 
2017). This finding was compatible with the clinical 
signs and the poorly controlled DM. Diagnostic imag-
ing was advised but declined by the owners. Both sur-
gical and medical options were discussed. The owners 
elected a medical treatment with trilostane (Vetoryl®, 
Dechra Limited, North Yorkshire, UK; 10 mg BID). 
The dose of glargine was lowered to 4 IU BID be-
cause the treatment of HC could lead to an improved 
sensitivity to insulin.
A control examination four weeks later (day 54) re-
vealed some improvement of the pupd. The results of 
HMBG showed constant hyperglycemia with a nadir 
of 18.6 mmol/L. Serum biochemistry revealed mild 
azotemia (creatinine 153 μmol/L, IRIS stage II). This 
has been previously described in cats on trilostane 
therapy (Mellett Keith et al., 2013). Thoracic radio-
graphs were performed for further work-up of poorly 
controlled diabetes mellitus and for detection of po-
tential concurrent abnormalities. No clinically signifi-
cant abnormalities were found. An ACTH-stimulation 
test showed an optimal post-ACTH cortisol level 
(Table 3). It is recommended to perform this test four 
to six hours after administration of trilostane (Neiger 
et al., 2004). The aim of treatment should be clinical 
improvement in combination with post-ACTH serum 
cortisol concentrations between 50 and 150 nmol/L 
(Niessen et al., 2013). Electrolytes in the present case 
were within normal limits. The same dose of trilostane 
was continued. The dosage of glargine was increased 
to 5 IU BID. 
At the next control examination, six weeks later 
(day 103), pupd was still present. HMBG still showed 
an insufficient glycemic control, hence the dose of 
glargine was increased (6 IU BID). Mild azotemia 
persisted. Urinalysis was advised but was difficult to 
perform because of the cat’s aggressive nature.  
Figure 4. Post-contrast computed tomographic images (transverse image on the left side and mid sagittal image on the 
right side) showing a strongly, mildly heterogeneously, enhancing mass lesion in the pituitary fossa corresponding to a 
pituitary macroadenoma (black arrows). 
Table 2. Results of low dose dexamethasone suppression test (LDDST) in a fourteen-year-old cat with diabetes and 
suspicion of hypercortisolism. A value > 40 nmol/L, 8 hours after dexamethasone administration, is consistent with HC 
(Boland and Barrs, 2017). 
Sample 1 (T0) Sample 2 (4h)  Sample 3 (8h)
69 nmol/l 39 nmol/l 55 nmol/l
Table 3. Results of ACTH stimulation tests, used as follow-up in a fourteen-year-old cat with hypercortisolism treated 
with trilostane. Day 0 = first presentation in clinic. 
Day  Dose trilostane  Dose trilostane Sample 1:  Sample 2: 
of test  after test basal cortisol post-ACTH
54 10 mg BID 10 mg BID 22 nmol/l 105 nmol/l
138 10 mg BID 8 mg BID 11 nmol/l 41 nmol/l
257 8 mg BID 7 mg BID  17 nmol/l 30 nmol/l
383 7 mg BID 5 mg BID 8 nmol/l 19 nmol/l
453 5 mg BID 5 mg BID 25 nmol/l 52 nmol/l
474 5 mg BID 0 mg 30 nmol/l 50 nmol/l
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Table 4. Sensitivity and specificity of tests that can be performed on cats to detect and/or differentiate hypercortisolism.
Test  Reference  N  Sensitivity Specificity Remarks 
LDDST Niessen et al. (2013) /  Very good Poor 
 Chiaramonte and Greco (2007) / / / Test of choice by many authors
 Feldman (2014) 58 100 % Was not critically 47 cats of their series and
    assessed  11 cats from the literature:
     Immink et al. (1992) (two cats) –
     Goossens et al. (1995) (three cats) –
     Meij et al.  (2001) (three cats) –
     Neiger et al. (2004) (three cats)
 Valentin et al. (2014) 28 / / Twenty-seven of twenty-eight tests
     were consistent with HAC and one
     was equivocal
ACTH Niessen et al. (2013) / Lack / In two thirds, the cortisol is 
stimulation     in normal range
test 
 Chiaramonte and Greco (2007) / / / Only 50-60 % with HAC show
     exaggerated response to ACTH
     administration  
 Feldman (2014)  65 33 %  Questionable 51 cats of their series and 14 cats from
     the literature: Immink et al. (1992)
     (one cat) – Schwedes (1997) (one cat) –
     Watson and Herrtage (1998) (five cats)
     – Moore et al. (2000) (one cat) –
     Skelly et al. (2003) (one cat) –
     Neiger et al. (2004) (five cats)
 Valentin et al. (2014) 37  All samples : At 30 min : 89 %
   56 %
   At 60 min At 60 min: 89 % 
   89 %
    
UC/CR Niessen et al. (2013) / Most sensitive / Elevated UC/CR could be result 
   screening test  of concurrent illness and stress
 Chiaramonte and Greco (2007) / / / Also high in cats with non-adrenal
     illness and so, is false-positive high.
     High cortisol:creatinine ratio in cats
     with concurrent disease should be
     confirmed with a LDDST (0,1 mg/kg
 Feldman (2014) 48 Ok Not ok  They included 28 cats of their series
     and 20 cats from the literature:
     Goossens et al. (1995) (six cats) -
     Schwedes (1997) (one cat) - Skelly et
     al. (2003) (one cat) - Meij et al. (2001)
     (seven cats) - Neiger et al. (2004)
     (five cats) 
 Goossens et al. (1995) 6 Sensitive Not mentioned
On day 138, the ACTH-stimulation test revealed 
a low post-ACTH cortisol level (Table 3). The dose 
of trilostane was decreased to 8 mg BID (pharma-
ceutically compounded). The HMBG curve showed 
periods of hypoglycemia and the dose of insulin was 
decreased to 4 IU BID. The azotemia (202.4 μmol/L, 
IRIS stage II) was mildly increased compared to the 
previous control, and ideally, a urinalysis should have 
been performed, but was again impossible because of 
the cat’s aggressive nature. It was advised to make a 
mix of diabetic and renal food (50/50) because of the 
high protein levels in the diabetic food. 
The next control examination on day 257 (Table 3) 
again led to a decrease of the trilostane (7 mg BID) 
and glargine (1.5 IU BID) dose. Urinalysis showed 
renal proteinuria (UPC 0.52, inactive sediment, nega-
tive culture) and isosthenuria (1,014). The mild azote-
mia was still present. However, according to the own-
ers, pupd was significantly decreased. 
During the next three months, the insulin therapy 
was tapered and could finally be stopped. More than 
one year after the first consultation, remission of dia-
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betes mellitus was suspected. Weekly monitoring of 
the glucose level, four hours after each meal, was 
recommended to detect possible relapse of diabetes 
mellitus. A month after stopping the insulin therapy 
(day 383), a control ACTH-stimulation test showed 
again a low post-ACTH cortisol level (< 50 nmol/L) 
and the dose of trilostane was decreased to 5 mg BID 
(Table 3). The azotemia (creatinine 222 μmol/L, IRIS 
stage II) was stable to mildly progressive and a con-
trol urinalysis showed borderline proteinuria. The 
owners mentioned pupd and weight loss. Because the 
cat was in diabetic remission and the azotemia was 
mildly progressive, the diet was changed to a strictly 
renal diet. Stopping diabetic diet can increase the risk 
of relapse; however, a renal diet was elected because 
the progressive azotemia was estimated to be more 
important (Sparkes et al., 2015). Thyroxine (T4) con-
centration, to exclude concomitant hyperthyroidism 
because of the weight loss, was within the reference 
range. 
On day 453, the cat presented with compulsive be-
havior; walking around the table aimlessly. A planti-
grade stance was present. Eating and drinking behavior 
was normal, but weight loss was noticed (400 g). The 
cat received trilostane 5 mg BID and the ACTH-stim-
ulation test showed a good control of HC (Table 3). 
The owners declined further diagnostic imaging.
During the next month, the neurological signs 
worsened and the cat developed an unsteady gait. On 
day 474, the post-ACTH cortisol level was borderline 
and trilostane was stopped because of deterioration of 
the general condition of the cat (Table 3). The neuro-
logical signs disappeared but one month later, the cat 
started to circle to the right. He also seemed blind. 
The temporarily improvement of the clinical signs 
was probably because stopping trilostane caused an 
increase in serum cortisol and hence the symptoms 
were reduced. Since the history of HC and the current 
neurological signs, there was a suspicion of a mac-
roadenoma and a CT-scan was re-advised. The CT 
scan (day 562) confirmed a large asymmetric, strong-
ly contrast-enhancing mass in the pituitary fossa 
extending dorsally out of the sella turcica (Figure 4). 
Treatment options were discussed with the owner. 
Considering the life-quality and life expectancy, the 
owners elected euthanasia. 
DISCUSSION
Insulin resistance is defined as present in a cat with 
poorly controlled DM on an insulin dosage greater 
than 1.5 IU/kg per injection (Scott-Moncrieff, 2010; 
Caney, 2013). It is important to differentiate insulin 
resistance from other causes of poor glycemic control, 
such as administration difficulties and insulin-related 
factors. A thorough history and demonstration of an 
injection by the owner may help to exclude many in-
terfering factors. If no management problem can be 
found, further investigations are required (Scott-Mon-
crieff, 2010; Sparkes et al., 2015). 
Assessment for concurrent diseases includes uri-
nalysis and culture, hematology and serum biochem-
istry, abdominal imaging and thoracic radiographs. 
Serum feline pancreatic lipase measurement can be 
valuable in the diagnosis of pancreatitis. Especially 
hypersomatotropism (acromegaly) but also HC are 
important causes of severe insulin resistance. Hyper-
somatotropism is evaluated by a measurement of se-
rum insulin-like growth factor-1. In this case, hyper-
somatotropism was considered highly unlikely due to 
IGF-1 measurement, performed several months after 
the insulin treatment had been started (Caney, 2013; 
Roomp and Rand, 2013; Sparkes et al., 2015; Ramsey 
and Herrtage, 2017). Since the hepatic growth hor-
mone receptors are stimulated by insulin for the pro-
duction of IGF-1, the concentrations of IGF-1 may be 
low in untreated diabetic cats and may increase during 
treatment with insulin. Therefore, it is important to 
treat diabetic cats first, before measurement of IGF-1 
(Reusch et al., 2006; Ramsey and Herrtage, 2017).  
There are multiple tests to diagnose HC in cats. All 
have advantages and disadvantages. In Table 4, their 
sensitivity and specificity are listed up. The LDDST 
is based on suppression of the cortisol level by ad-
ministration of dexamethasone in normal cats. Cats 
need a higher dose of dexamethasone (0.1 mg/kg in-
travenously) than dogs because a high percentage of 
normal cats do not experience the suppressive effects 
of dexamethasone in lower dose (Chiaramonte and 
Greco, 2007; Scott-Moncrieff, 2010; Niessen et al., 
2013). An ACTH stimulation test can also be used for 
screening. This test is based on the adrenal glands pro-
ducing excessive amounts of cortisol after stimulation 
in cats with HC compared to normal cats (Niessen et 
al., 2013). Urine cortisol/creatinine ratio (UCCR) can 
be used as an initial screening test. Additionally, the 
ratio can be used to differentiate between pituitary-
dependent (PDH) and adrenal-dependent HC (ADH), 
if the suppression test with dexamethasone is per-
formed. The advantage of this test is that it can be 
performed at home by collecting morning urine. If 
there is more than 50 % of suppression of the aver-
age UCCR after administration of dexamethasone, it 
is suggestive for PDH (Goossens et al., 1995; Nies-
sen et al., 2013). The reference range for UCCR and 
cortisol post-ACTH is laboratory specific. There are 
other tests like measuring endogenous adrenocortico-
tropic hormone (ACTH) and pro-opiomelanocortin, 
but these will not be further discussed (Niessen et al., 
2013). In this case, a LDDST was suggestive of PDH.
Besides endocrine testing, medical imaging is ad-
vised. Abdominal ultrasonography, CT and MRI can 
be used to image the adrenal glands and the pituitary 
gland. Reports on ultrasound of the adrenal glands of 
cats with PDH are limited. Similar to dogs, the major-
ity of cats with PDH show bilateral enlargement of 
the adrenal glands with retention of the normal shape. 
However, few cases with normal sized adrenal glands 
or mild asymmetric enlargement, as described in this 
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case report, have been reported. (Combes et al., 2013; 
Valentin et al. 2014; Boland and Barrs, 2017). In cats 
with ADH, the most important finding is a unilateral 
adrenal mass, with normal or small contralateral gland 
(Valentin et al., 2014; d’Anjou and Penninck, 2015; 
Boland and Barrs, 2017). The pituitary gland can be 
visualized by CT and MRI. About 50 % of pituitary 
tumors are large enough in size to visualize (Chiara-
monte and Greco, 2007; Niessen et al., 2013; Boland 
and Barrs, 2017). Generally, tumors smaller than 10 
mm in height are considered microtumors, whereas 
the larger masses are macrotumors. Microtumors are 
challenging to diagnose on imaging, whereas macro-
tumors are well-defined, strongly contrast-enhancing 
masses in the sellar region (Wisner and Zwingerberger, 
2015).
The cat described in this case report was treated 
with lente insulin after initial diagnosis of DM and 
then switched to a longer-acting insulin (glargine). 
At the time the cat was examined, only one insulin 
with a veterinary license for cats was available in Bel-
gium, i.e. Caninsulin® (MSD Animal Health, Brus-
sels, Belgium). It is a porcine insulin zinc suspension 
with an insulin concentration of 40 IU/ml. Because 
of the poor control of DM, and because glargine and 
protamine zinc insulin (PZI) have a longer duration of 
action, the treatment was changed to glargine by the 
referring veterinarian. At time of diagnosis and fol-
low-up, PZI was not registered in Belgium. Glargine 
is a long-acting synthetic insulin analogue. PZI has a 
similar duration of action as glargine in healthy cats 
(Marshall et al., 2008). A difference between PZI and 
glargine is the time to reach the first nadir glucose 
concentration. This is significantly shorter for PZI 
than for glargine but the time to reach the last nadir 
is similar, i.e. 14 hours (Marshall et al., 2008). Cur-
rently, proZinc® (Boehringer Ingelheim, Ingelheim, 
Germany) is available in Belgium. In several studies, 
a better glycemic control and higher remission rates 
with glargine and PZI have been suggested than with 
lente insulin (Boari et al., 2008; Marshall et al., 2009; 
Nelson et al., 2009; Roomp and Rand, 2009). How-
ever, it should be emphasized that the current level of 
evidence of all studies is moderate to poor. Common 
reasons of bias are lack of randomization and blind-
ing, poor study design and small sample size (Goste-
low et al., 2014). 
In the literature, a dose of insulin > 1.5 IU/kg per 
injection is considered a cut-off value for insulin re-
sistance, although it is often recommended to inves-
tigate causes of poorly controlled DM at lower dos-
ages of insulin, like in this case (Sparkes et al., 2015). 
In the present case, HC was diagnosed and medical 
treatment was started with trilostane. Trilostane is 
an inhibitor of the 3β-hydroxysteroid dehydrogenase 
enzyme. This enzyme has an essential role in the 
synthesis of steroids (Ramsey and Herrtage, 2017). 
There are currently no pharmacokinetic data avail-
able for trilostane in cats and only few reports of cats 
with HC treated with trilostane. In two case reports, 
each on one cat (i. e. one cat with PDH and one cat 
with bilateral adrenal enlargement with excessive sex 
hormone production), improvement of clinical signs 
has been described. In both cases, the initial dosage 
was 30 mg once daily (Skelly et al., 2003; Boag et 
al., 2004). In the cat with PDH, the dosage was in-
creased to 30 mg twice daily. Therapy was stopped 
when the cat became anorexic. An ACTH stimulation 
test was not performed, so iatrogenic hypocortisolism 
could not be ruled out. The cat died of renal failure. It 
was not clear if renal toxicity due to trilostane was in-
volved (Skelly et al., 2003). A study on five cats with 
PDH described two cats that died after 16 and 140 
days but three others were still alive after 6, 11 and 20 
months, respectively. Three cats were diagnosed with 
DM but continued to require insulin after treatment 
with trilostane was started. In all cats, a few days af-
ter starting trilostane therapy, clinical signs were im-
proved. Final dosages of 5.4 mg/kg once daily and 
7 mg/kg twice daily were used (Neiger et al., 2004). 
The largest and most recent study by Mellett Keith et 
al. (2013) included fifteen cats with spontaneous HC; 
fourteen cats were diagnosed with PDH and one cat 
with ADH. An improvement of the clinical signs and 
of the ACTH stimulation test results was described in 
13 of the 15 cats. In that study, diabetes mellitus was 
reported in 9/15 cases. In 6/9 cats with diabetes the in-
sulin requirements could be decreased by 36 % within 
two months. The median survival time was 617 days 
for all cats. The mean final dose of trilostane used, 
was 2.7 mg/kg once daily and 5.6 mg/kg twice daily. 
Four cats had changes consistent with chronic kidney 
disease (CKD) on medical imaging (Mellett Keith et 
al., 2013). Compared to the previous case reports, the 
cat in the current case was treated with a lower dose 
of trilostane (+/- 2 mg/kg twice daily starting dose), 
which could be tapered based on clinical improvement 
and ACTH stimulation test results. Possible explana-
tions for this difference could be an increased aware-
ness of the disease in cats, and therefore diagnosis at 
an earlier stage, lower starting dosage of trilostane, as 
well as improved follow-up by routine performance 
of ACTH stimulation tests. A similar evolution has 
been observed in dogs treated for hyperadrenocorti-
cism, as the initial manufacture’s starting dose recom-
mendation (3-6 mg/kg once daily) was much higher 
than the currently advised dose (2 mg/kg once daily) 
of Vetoryl® (Dechra Limited, North Yorkshire, UK) 
(Pérez-Alenza and Melian, 2017). In the current case, 
the cat developed progressive azotemia during treat-
ment. It should be emphasized that before treatment, 
the urine specific gravity (USG) was 1.015 although 
the majority of cats with HC have a USG of >1.020 
(Feldman, 2014; Boland and Barrs, 2017). It is un-
clear if the azotemia was caused by therapy or if the 
CKD had already been developing before treatment. 
Up till now, no cases have been reported where 
remission of DM occurs in cats with HC treated with 
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trilostane. However, the cat in this case went into re-
mission after 356 days of therapy with trilostane. At 
day 474, trilostane was stopped because of deterio-
ration of the general condition of the cat. Iatrogenic 
hypoadrenocorticism, due to necrosis of the adrenal 
gland cortex, appeared less likely based on ACTH-
stimulation test results (Ramsey, 2010). 
No studies have been published in cats on the opti-
mal timing to perform an ACTH stimulation test after 
drug administration. Based on studies in dogs and a 
similar cortisol nadir after trilostane administration in 
dogs and cats, a similar timing for the ACTH stimu-
lation test seems justified in cats (four to six hours 
after trilostane administration) (Neiger et al. 2004). 
Post-ACTH serum cortisol concentrations should be 
between 50 and 150 nmol/L. These values are labo-
ratory specific (Niessen et al., 2013). Trilostane is 
the medical treatment recommended above all other 
medical options because of its superior efficacy, rela-
tive lack of side effects and ease of use. Other medical 
treatment options are mitotane, ketoconazole, amino-
glutethimide and metyrapone but they are not recom-
mended due to the lack of efficacy in some cats, their 
adverse effects and the difficulty of sourcing them 
(Niessen et al., 2013; Boland and Barrs, 2017).
Surgical treatment of feline HC depends on the 
type of HC. If a single adrenal tumor is present, adre-
nalectomy is recommended. Bilateral removal of the 
adrenal glands has been described in case of bilateral 
adrenal tumors or PDH; however, in that case, the pa-
tient needs to be treated for hypoadrenocorticism after 
the removal (Chiaramonte and Greco, 2007; Niessen 
et al., 2013). Hypophysectomy is the best theoretical 
option in cats with PDH (Meij et al., 2001; Bhatti and 
Daminet, 2004; Niessen et al., 2013). In one study, 
microsurgical transsphenoidal hypophysectomy has 
been described in seven cats with HC (Meij et al., 
2001). Two cats died within four weeks after surgery. 
The other five cats went into both clinical and bio-
chemical remission of HC two months after hypophy-
sectomy with a median survival time of 15 months 
with a range of 6 to 46 months; two of the cats were 
still alive at the time of publication. One cat showed 
recurring signs of HC 19 months after surgery. The 
most important postoperative complications were 
oronasal fistula, transient reduction of tear production 
and wound dehiscence of the soft palate. Meij et al. 
(2001) concluded that a learning curve is necessary 
when treatment of PDH with hypophysectomy is in-
troduced but that it may offer a better quality of life and 
a higher survival rate than bilateral adrenalectomy or 
medical management. The owner initially refused ad-
vanced medical imaging and surgical treatment. The 
overall survival time in this case was 535 days since 
the diagnosis of HC. Based on the described case and 
previous publications, medical treatment could be a 
valuable alternative to surgical treatment in cats with 
HC (Skelly et al., 2003; Boag et al., 2004; Neiger et 
al., 2004; Mellet Keith et al., 2013).  
Although time-consuming and expensive, radia-
tion therapy is another treatment option (Chiaramonte 
and Greco, 2007). Only a small number of cats treated 
with pituitary irradiation have been described in the 
veterinary literature; however, the results indicate it 
could be a valuable option (Mayer et al., 2006). The 
median survival time in a study with eight cats was 
523 days, another study with five cats had survival 
rates of 5.5, 8, 15, 18, 20.5 months. Alopecia, color 
change of hair, hair depigmentation, atrophy of the 
epidermis and epilation in the treatment field are de-
scribed complications (Kaser-Hotz et al., 2002; May-
er et al., 2006). In the study by Mayer et al. (2006), 
in one cat out of eight, an acute aural adverse effect 
was seen. Bilateral cataracts, most likely an adverse 
effect of radiation therapy, was diagnosed in one cat 
of eight, thirteen months after treatment (Mayer et 
al., 2006). Similarly, as the median survival time with 
trilostane treatment is approximately 600 days and 
seems to be overall well-tolerated (cf. the current case 
and previous publications), medical treatment of HC 
in cats could be a valuable alternative (Neiger et al., 
2004; Mellett Keith et al., 2013). 
In the study of Mayer et al. (2006), in only four 
of the eight cats, follow-up brain imaging was per-
formed: two cats had a decreased tumor size at six 
and eight months after radiation and two cats had un-
changed tumor size at three and five months, respec-
tively. Kaser-Hotz et al. (2002) described follow-up 
CT examination performed in four cats. In one cat, 
the mass had disappeared, and in three cats, the mass 
was stable or had decreased slightly in size. The ideal 
treatment protocol with radiation still needs to be 
established (Kaser-Hotz, 2002; Mayer et al., 2006; 
Chiaramonte and Greco, 2007).
CONCLUSION
In the present case report, a cat with combined dia-
betes mellitus and HC medically treated with long-
acting insulin and trilostane is described. HC is rare in 
cats but important to consider in case of insulin resis-
tance. The cat in this report was successfully treated 
with trilostane and had a good quality of life. Diabetic 
remission was achieved.
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